Icatibant Piramal

Icatibant, the active ingredient in Icatibant Piramal, is a Bradykinin B2 receptor antagonist presented as a solution for injection for subcutaneous use. It treats hereditary angioedema attacks in patients with a confirmed diagnosis.

GNH USA supplies Icatibant Piramal as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is a selective bradykinin B2 receptor antagonist used in the management of hereditary angioedema.

- Hereditary angioedema type I: provides rapid reduction of swelling during acute attacks. - Hereditary angioedema type II: alleviates edema by blocking bradykinin effects. - Acute HAE attacks in adults: delivers prompt symptom control to improve patient comfort.

Icatibant may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Erythema: localized redness around the injection area. - Nausea: occasional feeling of queasiness after dosing. - Headache: transient head pain reported by some patients.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Hypotension: sudden drop in blood pressure that may cause dizziness. - Angioedema at injection site: swelling that can extend beyond the local area. - Urticaria: hives or widespread skin rash.

Before using Icatibant, consider the following safety measures.

- Pregnancy: safety not established; use only if benefits outweigh potential risks. - Breastfeeding: unknown effects; evaluate risk versus benefit. - Renal impairment: administer with caution and monitor renal function. - Concomitant ACE inhibitors: may increase risk of angioedema; monitor closely. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that affect bradykinin pathways.

Major Interactions (Avoid): - ACE inhibitors: may potentiate bradykinin effects, raising angioedema risk. - Neprilysin inhibitors (e.g., sacubitril): increase bradykinin levels, potentially worsening swelling.

Moderate Interactions (Monitor Closely): - Estrogen‑containing oral contraceptives: may exacerbate hereditary angioedema. - Angiotensin receptor blockers: possible additive effect on bradykinin activity. - Diuretics: monitor fluid balance and blood pressure during therapy.